AZ-MANGATA-NETWORKS
16.9.2020 18:02:09 CEST | Business Wire | Press release
Mangata Networks announced today that it has been selected as a member of the 5G Open Innovation Lab, a global ecosystem of developers, start-ups, enterprises, academia and government institutions, focused on helping start-ups utilize 5G to develop new capabilities, use cases and market categories. Mangata Networks will work closely with the Lab’s founding partners including Intel, T-Mobile and other partners to further develop its 5G over satellite network solution. MangataEdgeTM will be a bit more than a satellite terminal integrating microEdge cloud computing with 5G radio access networking capability.
Brian Holz, CEO of Mangata Networks said “the 5G Open Innovation Lab is a fantastic opportunity for our team. We look forward to working with TMobile, Intel and their partners to further develop and define our core terrestrial networking product, ensuring seamless integration into 5G networks at affordable costs. MangataEdgeTM will allow operators to bring the cloud directly to businesses, communities and individuals, enabling them to effectively do their bit.”
Unique to the Lab’s approach is its focus on unifying an independent ecosystem by bringing together technology, financial and community partners and forward-thinking customers from industries such as media and entertainment, transportation, oil and gas, manufacturing, and retail.
Integrating satellite over 5G in a seamless, cost-effective manner enables information exchange and service delivery by communities and individuals not well connected today. The 5G Open Innovation Lab will give Mangata Networks access to leading edge technology, partnerships, resources, and environment to ensure their 5G product is a success.
“The 5G OI Lab is an extraordinary opportunity for developers to work directly with technology and business leaders to design and bring to life their vision and dreams for new 5G applications,” said Jim Brisimitzis, managing partner of the 5G OI Lab. “This is not just any startup program. We are building a true partner ecosystem that will bring knowledge, resources and capital together to change the world in profound ways.”
About the 5G Open Innovation Lab
The 5G Open Innovation Lab (5G OI Lab) is a global ecosystem of developers, start-ups, enterprises, academia and government institutions working together to fuel the development of new 5G capabilities and market categories that will transform the way we work, live and play both now and in the future. The Lab provides developers at all stages unparalleled access to open platforms, enterprises and markets needed to create, test and deploy new use cases and innovations for 5G. To learn more about the Lab and its portfolio of companies, please visit https://www.5GOILab.com/ or follow us on Twitter at @5GOILab.
About Mangata Networks
Mangata Networks, a joint venture with Intellectual Ventures Invention Science Fund, is a satellite enabled telecommunications company seeking to transform human potential into action. Our solution: creating a seamless global network to support businesses, communities, and individuals to do their bit. Our single core network allows rapid scaling of data connectivity across geographies. With a global footprint, our technology can be mobilized by businesses to reach their highest potential anywhere at an affordable price. To learn more about Mangata Networks, please visit https://www.mangatanetworks.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005591/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom